

[New Clinical Trial Recruiting Mesothelioma Patients For A New Treatment Strategy](#)

(Posted by Tom Lamb at www.AsbestosHUB.com on February 19, 2010; see <http://bit.ly/9HTKFJ>)

Sponsored by Eli Lilly and the University Health Network in Toronto, Canada, a new clinical trial is designed to test the effectiveness of Permetrexed, a drug used to treat mesothelioma, combined with Cisplatin and followed by surgery and radiation therapy. Participants in the trial will receive IV infusions of Alimta and Cisplatin every three weeks within a three cycle period.

From a “Mesothelioma Alert” announcing the recruitment:

Oncologists and drug researchers believe that a combination of Pemextred, a chemotherapy drug marketed as Alimta, is especially effective in treating patients with [pleural mesothelioma](#) when combined with Cisplatin, another anti-cancer medicine. The duo has been approved as a standard course of treatment for those suffering from this type of cancer.

We are reminded that interested parties should first speak with their physician or an oncologist before contacting trial representatives.

Visit [TransWorldNews to read the full Mesothelioma Alert](#) and get further details on how to participate.

Attorney [Tom Lamb](#) represents people in personal injury and wrongful death cases involving mesothelioma or other asbestos cancers. The above article was posted originally on his blog, **Asbestos HUB** – with active links and readers’ comments.
<http://AsbestosHUB.com>